Drs Neal and Rolfo discuss the significance of the FDA approval of taletrectinib for the treatment of locally advanced or metastatic, ROS1-positive NSCLC.
Christian Rolfo, MD, PhD
Advertisement
Christian Rolfo, MD, PhD, is the director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—James and a professor in the College of Medicine at The Ohio State University
Articles by Christian Rolfo, MD, PhD
Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.
Advertisement
Latest Updated Articles
Dr. Rolfo on Precision Medicine in Lung CancerPublished: January 12th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5